Chronobiological aspects of fear extinction by d-cycloserine and valproic acid

Chronobiological aspects of fear extinction by d-cycloserine and valproic acid - Chronobiological aspects of fear extinction by d-cycloserine and valproic acid

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000003833

Enrollment

Registered

2010-07-01

Start date

2010-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anxiety disorder

Interventions

placebo (sugar lactate (SL)) 500mg/ morning-evening schedule placebo (sugar lactate (SL)) 500mg/ evening-morning schedule d-cycloserine 100mg + SL 400mg/ morning-evening schedule d-cycloserine 100mg +

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Healthy subjects who had no history of drug or alcohol abuse or of neurological, psychiatric, or sleep disorders, and were maintaining a constant sleep schedule

Exclusion criteria

Exclusion criteria: Healthy subjects who had one or more histories of drug or alcohol abuse or of neurological, psychiatric, or sleep disorders, and/or were not maintaining a constant sleep schedule

Design outcomes

Primary

Measure	Time frame
Skin conductance response	—

Secondary

Measure	Time frame
Task performances (Accuracy, response time)	—

Countries

Japan

Contacts

Public ContactKenichi Kuriyama

National Center of Neurology and Psychiatry Department of Adult Mental Health

kenichik@ncnp.go.jp042-346-1986

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026